[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100287506":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":32,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":64,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"NYU Langone Health","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"MINOCA",null,"Women with myocardial infarction (MI) with demonstrated non-obstructive coronary artery disease during cardiac catheterization (less than 50% blockage in any major vessel).",{"label":13,"type":10,"description":14,"interventionNames":10},"MI-CAD","Women with myocardial infarction (MI) with demonstrated obstructive coronary artery disease during cardiac catheterization (50% or greater blockage in any major vessel) or previous history of percutaneous coronary intervention (PCI) or or coronary artery bypass graft (CABG).",{"label":16,"type":10,"description":17,"interventionNames":10},"CATH-NOCA","Women with stable angina that are age and race matched to women in the MINOCA arm that are clinically referred for cardiac catheterization",[19],{"name":20,"affiliation":21,"role":22},"Harmony R Reynolds, MD","NYU Langone Medical Center","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Jeffrey Berger, MD","CONTACT","212 263 4004","jeffrey.berger@nyumc.org",{"name":20,"role":26,"phone":30,"phoneExt":10,"email":31},"917-693-7070","harmony.reynolds@nyumc.org",[33],{"facility":21,"status":34,"city":35,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","New York","10016","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-74.00597,40.71427,{"lat":43,"lon":42},[46],{"name":25,"role":26,"phone":10,"phoneExt":10,"email":10},{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100287506","heart-attack-research-program-platelet-sub-study-harp-100287506",false,"NCT03022552","Heart Attack Research Program: Platelet Sub-Study (HARP)","Heart Attack Research Program: Platelet Sub-Study (HARP); Platelet Collection for Patients With Myocardial Infarction","HARP","Inclusion Criteria:\n\n* Acute ischemic symptoms compatible with diagnosis of MI, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms\n* Objective evidence of MI (either or both of the following):\n\n  * Elevation of troponin to above the laboratory upper limit of normal (ULN)\n  * ST segment elevation of ≥1mm on 2 contiguous ECG leads\n* Willing to provide informed consent and comply with all aspects of the protocol\n* Administration of aspirin at least 1 hour before cardiac catheterization\n* Administration of thienopyridine (e.g., clopidogrel, ticagrelor) at least 1 hour before cardiac catheterization\n* Women and men with ≥50% of any major epicardial vessel on invasive angiography may participate\n\nExclusion Criteria:\n\n* Recent use of vasospastic agents, such as cocaine, triptans, or ergot alkaloids (≤1 month)\n* Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma\n* Pregnancy\n* Thrombolytic therapy for STEMI (qualifying event)\n* Use of any of the following medications:\n* Platelet antagonists (except aspirin and thienopyridines) within 7 days\n* NSAIDs (e.g., ibuprofen, naproxen) within 3 days.\n* Thrombocytopenia (platelet count \\\u003C100,000)\n* Thrombocytosis (platelet count \\>500,000)\n* Anemia (hemoglobin \\\u003C9 mg\u002Fdl)\n* Hemorrhagic diathesis",true,"FEMALE","21 Years","99 Years",{"count":62,"type":63},350,"ESTIMATED","6 Months","OBSERVATIONAL","This prospective observational cohort study, will investigate the platelet phenotype, platelet genetic composition, and role of platelets as effector cells in women and men with myocardial infarction (MINOCA or MI-CAD) and controls. This study, which will take place at NYU and Bellevue Medical Center, and participating external sites. May have concurrent enrollment with the HARP Main Imaging (NCT02914483). Additionally, a sex, group of age and race matched disease controls 'CATH-NOCA' composed of women and men with stable angina referred for cardiac catheterization, will be enrolled. Blood obtained during the initial catheterization and 2 months post-MI will be utilized for platelet testing.",[68],"Myocardial Infarction",[68,70,71,72],"Platelets","Blood Collection","Genomics","2026-04-17",{"date":75,"type":76},"2026-04-20","ACTUAL",{"date":78,"type":76},"2020-07-01",{"date":80,"type":63},"2027-06-30",{"name":5,"class":6},1]